Nvidia and Eli Lilly and Co. are partnering to create an artificial intelligence lab in the San Francisco Bay Area to ...

Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs.

Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive ...

Cannabis produces a complex suite of bioactive compounds, including tetrahydrocannabinol (THC) and cannabidiol (CBD), but how ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

The biopharmaceutical sector finally regained its footing in 2025. Here are 5 issues that could determine whether the renewed ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Stoke Therapeutics and the FDA were unable to reach agreement on an expedited submission for the company’s severe epilepsy ...